NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis $15.39 -0.62 (-3.87%) (As of 11:15 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Pieris Pharmaceuticals Stock (NASDAQ:PIRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pieris Pharmaceuticals alerts:Sign Up Key Stats Today's Range$15.39▼$15.3950-Day Range$15.44▼$17.3052-Week Range$6.20▼$22.32Volume2,678 shsAverage Volume47,593 shsMarket Capitalization$20.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Pieris Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks33rd Percentile Overall ScorePIRS MarketRank™: Pieris Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 781st out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pieris Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.70% of the float of Pieris Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently decreased by 16.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.81 Percentage of Shares Shorted1.70% of the float of Pieris Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently decreased by 16.04%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.21 News SentimentPieris Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pieris Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Pieris Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.39% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pieris Pharmaceuticals' insider trading history. Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PIRS Stock News HeadlinesPIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRSNovember 20 at 5:29 PM | businesswire.comPieris Pharmaceuticals (NASDAQ:PIRS) Rating Increased to Hold at StockNews.comNovember 20 at 3:49 AM | americanbankingnews.comWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 21, 2024 | DTI (Ad)Pieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trialNovember 7, 2024 | markets.businessinsider.comAridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comPalvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual ConferenceOctober 15, 2024 | globenewswire.comPalvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic MalformationsOctober 3, 2024 | globenewswire.comKubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comSee More Headlines PIRS Stock Analysis - Frequently Asked Questions How have PIRS shares performed this year? Pieris Pharmaceuticals' stock was trading at $14.56 on January 1st, 2024. Since then, PIRS stock has increased by 5.7% and is now trading at $15.39. View the best growth stocks for 2024 here. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($19.20) EPS for the quarter, hitting analysts' consensus estimates of ($19.20). The biotechnology company earned $4.06 million during the quarter, compared to analysts' expectations of $7.98 million. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative trailing twelve-month return on equity of 80.93%. When did Pieris Pharmaceuticals' stock split? Pieris Pharmaceuticals's stock reverse split on the morning of Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Pieris Pharmaceuticals' major shareholders? Pieris Pharmaceuticals' top institutional shareholders include BML Capital Management LLC (3.19%) and Frazier Life Sciences Management L.P. (1.21%). Insiders that own company stock include Adar1 Capital Management, Llc, Christopher P Kiritsy and Tim Demuth. View institutional ownership trends. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), General Electric (GE) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/02/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PIRS CUSIPN/A CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees140Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,540,000.00 Net Margins-39.71% Pretax Margin-1,179.96% Return on Equity-80.93% Return on Assets-59.55% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$42.81 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value$12.32 per share Price / Book1.30Miscellaneous Outstanding Shares1,320,000Free Float1,236,000Market Cap$21.13 million OptionableOptionable Beta0.66 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:PIRS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.